Revisiting a Meta-analysis Shows that Hydroxychloroquine with Azithromycin may be Efficient in Covid-19 patients
Lounnas e al., Archives of Microbiology & Immunology, doi: (meta analysis)
Lounnas, Revisiting a Meta-analysis Shows that Hydroxychloroquine with Azithromycin may be Efficient in Covid-19.., e al., Archives of Microbiology & Immunology, doi: (meta analysis)
Analysis of the Fiolet meta analysis and correction of bias evaluation, showing HCQ RR 0.45 [0.31-0.59], and HCQ+AZ RR 0.34 [0.06-0.61].
Currently there are 36 HCQ early treatment studies
and meta analysis shows:
Lounnas et al., 9 Feb 2021, peer-reviewed, 4 authors.
Abstract: Arch Microbiol Immunology 2021; 5 (1): 154-175
Revisiting a Meta-analysis Shows that Hydroxychloroquine with
Azithromycin may be Efficient in Covid-19 patients
Valère Lounnas1, Alexis Lacout2*, Xavier Azalbert3, Christian Perronne4
EMBL Heidelberg alumni, Meyerhofstraße 1, 69117, Heidelberg, Germany
Centre de diagnostic ELSAN, Centre médico –chirurgical, Aurillac, France
Toulouse School of Economics, 1988 Econometrics, France
Service des Maladies Infectieuses et Tropicales, University of Versailles Saint Quentin – Paris Saclay,
University Hospital Raymond Poincaré, Garches, France
*Corresponding Author: Alexis Lacout, Centre de diagnostic ELSAN, Centre Médico–Chirurgical, 83
avenue Charles de Gaulle, 15000, Aurillac, France, Tel: +33 687273707, Fax: +33 471485348; E-mail:
Received: 22 January 2021; Accepted: 02 February 2021; Published: 09 February 2021
Citation: Valère Lounnas, Alexis Lacout, Xavier Azalbert, Christian Perronne. Revisiting a Meta-analysis
Shows that Hydroxychloroquine with Azithromycin may be Efficient in Covid-19 patients. Archives of
Microbiology & Immunology 5 (2021): 154-175.
regarding the toxicity of the association HCQ plus
Objective: To analyze the impact of study
AZI is made.
selection on the results of a recently published
Results: Meta-analyses performed on the 11
studies we deem critically unbiased show a
hydroxychloroquine plus azithromycin (AZI) in
mortality reduction of 55% for HCQ and 66% for
HCQ plus AZI.
Methods: 31 studies were reviewed looking for
For both treatments, our meta-analysis indicates a
significant efficacy in reducing mortality in
confidence intervals were calculated for both
hospitalized Covid-19 patients.
treatments using a fixed effects size model and a
Archives of Microbiology & Immunology
Vol. 5 No. 1 – March 2021
Arch Microbiol Immunology 2021; 5 (1): 154-175
Keywords: Covid-19; Meta-analysis; Critical
they rely blindly on their calculations to firmly
suggest that: (1) HCQ alone does not show efficacy
against Covid-19; and (2) any patient treated by
HCQ and AZI, at any stage of the disease, would
develop a high risk of cardiac failure subsequent to
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC
provide treatment protocols.